{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:11:55Z","timestamp":1760955115202},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,2,9]],"date-time":"2009-02-09T00:00:00Z","timestamp":1234137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Immune thrombocytopenic purpura and secondary thrombocytopenia patients treated with Rh<jats:sub>o<\/jats:sub>(D) immune globulin intravenous (human; anti\u2010D IGIV) have experienced acute hemolysis, which is inconsistent with the typical presentation of extravascular hemolysis\u2014the presumed mechanism of action of anti\u2010D IGIV. Although the mechanism of anti\u2010D\u2010IGIV\u2013associated acute hemolysis has not been established, the onset, signs\/symptoms, and complications appear consistent with the intravascular hemolysis of acute hemolytic transfusion reactions (AHTRs). In transfusion medicine, the red blood cell (RBC) antigen\u2010antibody incompatibility(\u2010ies) that precipitate AHTRs can be detected in vitro with compatibility testing. Under the premise that anti\u2010D\u2010IGIV\u2013associated acute hemolysis results from RBC antigen\u2010antibody\u2013mediated complement activation, this study evaluated whether the incompatibility(\u2010ies) could be detected in vitro with a hemolysin assay, which would support the AHTR model as the hemolytic mechanism.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Seven anti\u2010D IGIV lots were tested to determine the RBC antibody identities in those lots, including four lots that had been implicated in acute hemolytic episodes. Hemolysin assays were performed that tested each of 73 RBC specimens against each lot, including the RBCs of one patient who had experienced acute hemolysis after anti\u2010D IGIV administration.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> Only two anti\u2010D IGIV lots contained RBC antibodies beyond those expected. No hemolysis endpoint was observed in any of the hemolysin assays.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> Although the findings did not support the AHTR model, the results are reported to contribute knowledge about the mechanism of anti\u2010D\u2010IGIV\u2013associated acute hemolysis and to prompt continued investigation into cause(s), prediction, and prevention of this potentially serious adverse event.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2008.02083.x","type":"journal-article","created":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T05:12:28Z","timestamp":1234242748000},"page":"1050-1058","source":"Crossref","is-referenced-by-count":13,"title":["Investigation of whether the acute hemolysis associated with Rh<sub>o<\/sub>(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model"],"prefix":"10.1111","volume":"49","author":[{"given":"Ann Reed","family":"Gaines","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hallie","family":"Lee\u2010Stroka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothy E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Stroncek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,6]]},"reference":[{"key":"e_1_2_8_2_2","volume-title":"Rho(D) immune globulin intravenous (Human): WinRho\u00ae SDF [professional package insert","author":"Cangene Corporation","year":"2006"},{"issue":"1","key":"e_1_2_8_3_2","first-page":"9","article-title":"Safety profile of WinRho anti\u2010D","volume":"35","author":"Hong F","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.11.019"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2006.04.009"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20813"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.8.2689"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10424"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.9.1884.1884"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20996"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92205-5"},{"issue":"1","key":"e_1_2_8_12_2","first-page":"23","article-title":"Efficacy, safety, and dose response of intravenous anti\u2010D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children","volume":"35","author":"Freiberg A","year":"1998","journal-title":"Semin Hematol"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3282ab98df"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-004481"},{"key":"e_1_2_8_15_2","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.V95.8.2523","article-title":"Acute onset hemoglobinemia and\/or hemoglobinuria and sequelae following Rho(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients","volume":"95","author":"Gaines AR","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1993.tb05160.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000089465"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4303"},{"key":"e_1_2_8_19_2","volume-title":"Physician's desk reference","author":"Ortho Pharmaceuticals","year":"1981"},{"key":"e_1_2_8_20_2","first-page":"164","article-title":"Column ion exchange preparation and characterization of an Rh immune globulin (WinRho) for intravenous use","volume":"3","author":"Friesen AD","year":"1981","journal-title":"J Appl Biochem"},{"key":"e_1_2_8_21_2","first-page":"1121","article-title":"WinRho: Rh immune globulin prepared by ion exchange for intravenous use","volume":"123","author":"Bowman JM","year":"1980","journal-title":"Can Med Assoc J"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00902.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood.V91.7.2624","article-title":"Intravenous anti\u2010D treatment for immune thrombocytopenic purpura [letter","volume":"91","author":"Sandler SG","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470986868"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470987018"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200111000-00017"},{"key":"e_1_2_8_27_2","volume-title":"Immune hemolytic anemias","author":"Petz LD","year":"2004"},{"key":"e_1_2_8_28_2","volume-title":"Modern blood banking and transfusion practices","author":"Harmening DM","year":"2005"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.006"},{"key":"e_1_2_8_30_2","volume-title":"Technical manual","author":"Brecher M","year":"2005"},{"key":"e_1_2_8_31_2","volume-title":"Hematology: basic principles and practice","author":"Hoffman R","year":"2005"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40050551.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.001"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03290.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01283.x"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.10.014"},{"key":"e_1_2_8_37_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.21307\/immunohematology-2019-402","article-title":"Review: complement receptor 1 therapeutics for prevention of immune hemolysis","volume":"21","author":"Yazdanbakhsh K","year":"2005","journal-title":"Immunohematology"},{"key":"e_1_2_8_38_2","volume-title":"25th Annual Scientific Meeting","author":"Garratty G","year":"2007"},{"key":"e_1_2_8_39_2","first-page":"370","article-title":"The functional activity of human monocytes passively acquired with monoclonal anti\u2010D suggests a novel role for Fc gamma RI in the immune destruction of blood cells","volume":"83","author":"Griffiths HL","year":"1994","journal-title":"Immunology"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.04.005"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10432"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-001-0763-4"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200110000-00014"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2003.09.001"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200010)65:2<178::AID-AJH18>3.0.CO;2-G"},{"key":"e_1_2_8_46_2","unstructured":"ParkerC.Intravenous Rho[D] immune globulin [human] (WinRho SDF): suspected hemolytic\/renal adverse reactions.Can Med Assoc J163:881 885."},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/000992280104000114"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3854"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318142ac5f"},{"key":"e_1_2_8_50_2","volume-title":"Rho(D) immune globulin intravenous (human): Rhophylac [professional package insert","author":"Behring AG","year":"2007"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00244.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2008.02083.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2008.02083.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T13:35:15Z","timestamp":1697290515000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2008.02083.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1537-2995.2008.02083.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2008.02083.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}